Alcon stock buys Neurotech for USD 550 million pre-market
Published on 10/22/2026 at 08:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAcquisition and product expansion
- The eye-care group acquired Neurotech Pharmaceuticals on October 20, 2026, for USD 550 million.
- Alcon develops surgical and vision care products for eye-care markets.
- Alcon stock trades pre-market at EUR 59.73 at 8:06 a.m. CEST at Lang & Schwarz on October 22, 2026.
On October 20, 2026, Alcon announced that it had acquired Neurotech Pharmaceuticals for USD 550 million. The transaction adds ENCELTO, an FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, to Alcon’s retina portfolio, according to Business Wire.
Neurotech deal details
Alcon said ENCELTO is an encapsulated cell therapy intended for surgical implantation in patients with MacTel, a rare retinal disease. The company also said the acquisition may involve additional contingent payments tied to commercial milestones. Alcon expects the transaction to be modestly accretive to net sales growth and slightly dilutive to core diluted earnings per share in 2027, with accretion thereafter, the Business Wire release said.
Pre-market indication
Alcon stock trades pre-market at EUR 59.73 at 8:06 a.m. CEST at Lang & Schwarz on October 22, 2026. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Alcon stock.
Alcon's business mix
Alcon develops and sells surgical and vision care products for people with eye conditions, serving markets that include cataracts, glaucoma, retinal diseases, contact lenses and eye-care products, according to its investor-relations site.
Market context: Market report SMI.
